Diamond Hill Capital's PFE Position Overview
Diamond Hill Capital (via Diamond Hill Capital Management INC) currently holds 10.9M shares of Pfizer Inc. (PFE) worth $278.35 M, representing 1.32% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Diamond Hill Capital has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 5.2M shares. Largest reduction occurred in Q3 2025, reducing 6.7M shares.
Analysis based on 13F filings available since 2013 Q2
Diamond Hill Capital's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Diamond Hill Capital
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +7.95 M | Add 0.00% | 7.95 M | $28.01 |
| Q3 2013 | +40,561 | Add 0.51% | 7.99 M | $28.71 |
| Q4 2013 | +347,060 | Add 4.34% | 8.34 M | $30.63 |
| Q1 2014 | +451,874 | Add 5.42% | 8.79 M | $32.12 |
| Q2 2014 | +587,875 | Add 6.69% | 9.38 M | $29.68 |
| Q3 2014 | +816,955 | Add 8.71% | 10.2 M | $29.57 |
| Q4 2014 | +417,118 | Add 4.09% | 10.61 M | $31.15 |
| Q1 2015 | -180,534 | Reduce 1.70% | 10.43 M | $34.79 |
| Q2 2015 | -197,433 | Reduce 1.89% | 10.23 M | $33.53 |
| Q3 2015 | +146,004 | Add 1.43% | 10.38 M | $31.41 |
| Q4 2015 | +340,439 | Add 3.28% | 10.72 M | $32.28 |
| Q1 2016 | +524,230 | Add 4.89% | 11.25 M | $29.64 |
| Q2 2016 | +400,968 | Add 3.57% | 11.65 M | $35.21 |
| Q3 2016 | +209,704 | Add 1.80% | 11.86 M | $33.87 |
| Q4 2016 | +1.1 M | Add 9.28% | 12.96 M | $32.48 |
| Q1 2017 | -598,959 | Reduce 4.62% | 12.36 M | $34.21 |
| Q2 2017 | -1.03 M | Reduce 8.31% | 11.33 M | $33.59 |
| Q3 2017 | -203,127 | Reduce 1.79% | 11.13 M | $35.70 |
| Q4 2017 | -219,493 | Reduce 1.97% | 10.91 M | $36.22 |
| Q1 2018 | -1.4 M | Reduce 12.85% | 9.51 M | $35.49 |
| Q2 2018 | -951,533 | Reduce 10.01% | 8.56 M | $36.28 |
| Q3 2018 | -507,041 | Reduce 5.93% | 8.05 M | $44.07 |
| Q4 2018 | -745,581 | Reduce 9.26% | 7.3 M | $43.65 |
| Q1 2019 | +284,683 | Add 3.90% | 7.59 M | $42.47 |
| Q2 2019 | +114,064 | Add 1.50% | 7.7 M | $43.32 |
| Q3 2019 | +546,541 | Add 7.10% | 8.25 M | $35.93 |
| Q4 2019 | -118,232 | Reduce 1.43% | 8.13 M | $39.18 |
| Q1 2020 | +606,061 | Add 7.45% | 8.74 M | $32.64 |
| Q2 2020 | +63,223 | Add 0.72% | 8.8 M | $32.70 |
| Q3 2020 | -88,396 | Reduce 1.00% | 8.71 M | $36.70 |
| Q4 2020 | +467,368 | Add 5.37% | 9.18 M | $36.81 |
| Q1 2021 | +2.06 M | Add 22.49% | 11.24 M | $36.23 |
| Q2 2021 | +438,427 | Add 3.90% | 11.68 M | $39.16 |
| Q3 2021 | -1.04 M | Reduce 8.86% | 10.65 M | $43.01 |
| Q4 2021 | -825,746 | Reduce 7.76% | 9.82 M | $59.05 |
| Q1 2022 | -413,679 | Reduce 4.21% | 9.41 M | $51.77 |
| Q2 2022 | -293,502 | Reduce 3.12% | 9.11 M | $52.43 |
| Q3 2022 | -1.12 M | Reduce 12.26% | 8 M | $43.76 |
| Q4 2022 | -1.2 M | Reduce 14.96% | 6.8 M | $51.24 |
| Q1 2023 | -30,443 | Reduce 0.45% | 6.77 M | $40.80 |
| Q2 2023 | +131,305 | Add 1.94% | 6.9 M | $36.68 |
| Q3 2023 | -296,444 | Reduce 4.30% | 6.6 M | $33.17 |
| Q4 2023 | +5.19 M | Add 78.67% | 11.8 M | $28.79 |
| Q1 2024 | +4.31 M | Add 36.51% | 16.11 M | $27.75 |
| Q2 2024 | -210,435 | Reduce 1.31% | 15.9 M | $27.98 |
| Q3 2024 | +658,420 | Add 4.14% | 16.55 M | $28.94 |
| Q4 2024 | +2.07 M | Add 12.50% | 18.62 M | $26.53 |
| Q1 2025 | -6,832 | Reduce 0.04% | 18.62 M | $25.34 |
| Q2 2025 | -952,171 | Reduce 5.11% | 17.66 M | $24.24 |
| Q3 2025 | -6.74 M | Reduce 38.16% | 10.92 M | $25.48 |
Diamond Hill Capital's Pfizer Investment FAQs
Diamond Hill Capital first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 7,951,442 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital has held Pfizer Inc. (PFE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 7,951,442 shares worth $222.72 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Diamond Hill Capital's firm, Diamond Hill Capital Management INC, owns 10,924,267 shares of Pfizer Inc. (PFE), valued at approximately $278.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 1.32% of Diamond Hill Capital's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital's peak holding in Pfizer Inc. (PFE) was 18,623,356 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.